Table 3. AMH assay, lowest detected value (LDV) and AMH geometric means (95% CIs) for cases and controls.
| Cohort1 | Assay2 | LDV3, pmol/l | < LDV, % | Geometric mean4 (95% CI), pmol/l | Age-adjusted geometric mean4 (95% CI), pmol/l | |||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Cases | Controls | Cases | Controls | Cases | Controls | |||
| BGS | picoAMH ELISA | 0.0165 | 4.1 | 5.9 | 2.57 (2.12, 3.11) | 2.33 (1.91, 2.86) | 2.31 (2.00,2.67) | 1.95 (1.68,2.27) |
| CLUE II | picoAMH ELISA | 0.0165 | 3.7 | 2.9 | 4.71 (3.29, 6.75) | 4.14 (2.91, 5.90) | 1.85 (1.41,2.42) | 1.52 (1.14,2.01) |
| CSB | picoAMH ELISA | 0.0330 | 5.0 | 12.9 | 2.52 (1.67, 3.81) | 1.39 (0.91, 2.13) | 2.90 (2.15,3.92) | 1.61 (1.17,2.20) |
| Guernsey | picoAMH ELISA | 0.0264 | 5.7 | 2.8 | 3.12 (2.33, 4.17) | 3.68 (2.84, 4.78) | 1.29 (1.03,1.63) | 1.36 (1.07,1.73) |
| NHS | picoAMH ELISA | 0.0165 | 4.4 | 10.3 | 2.03 (1.45, 2.83) | 1.03 (0.71, 1.52) | 4.21 (3.24,5.46) | 2.22 (1.69,2.92) |
| NHSII | picoAMH ELISA | 0.0165 | 1.5 | 1.5 | 6.77 (5.83, 7.87) | 5.21 (4.47, 6.06) | 4.55 (3.90,5.30) | 3.15 (2.68,3.70) |
| NSMSC | picoAMH ELISA | 0.0165 | 6.1 | 7.6 | 1.00 (0.58, 1.70) | 0.71 (0.43, 1.18) | 2.98 (2.05,4.33) | 2.23 (1.51,3.31) |
| NYUWHS | picoAMH ELISA | 0.143 | 15.4 | 15.6 | 2.54 (2.21, 2.92) | 2.32 (2.02, 2.67) | 2.76 (2.47,3.08) | 2.40 (2.14,2.70) |
| ORDET | picoAMH ELISA | 0.0264 | 3.8 | 9.5 | 2.84 (2.25, 3.58) | 1.93 (1.48, 2.51) | 2.79 (2.31,3.36) | 1.93 (1.59,2.34) |
| Sister Study | Ultrasensitive & picoAMH ELISA5 | 0.0214 | 16.0 | 18.5 | 1.20 (0.93, 1.54) | 1.03 (0.85, 1.25) | 2.30 (1.96,2.70) | 1.80 (1.59,2.05) |
Cohort abbreviations: BGS: Breakthrough Generations Study; CLUE II: Campaign Against Cancer and Heart Disease; CSB: Columbia, Missouri Serum Bank; NHS: Nurses' Health Study; NHSII: Nurses' Health Study II; NSMSC: Northern Sweden Mammography Screening Cohort; NYUWHS: New York University Women's Health Study; ORDET: Hormones and Diet in the Etiology of Breast Cancer.
Assays were conducted at Ansh Labs, except for the NYUWHS (Core Laboratory, Massachusetts General Hospital Pathology Service) and the Sister Study (Reproductive Endocrinology Laboratory, University of Southern California).
LDV varied depending on the dilution factor used.
Subjects with AMH measurement below the LDV were assigned the value of LDV divided by the square root of 2. Age-adjusted means adjusted for age and age-squared. Samples with AMH above the highest detectable value (n=14 total, 3 from CLUE II and 11 from NYUWHS) were set to the highest detectable value.
All samples were measured using the Ultrasensitive assay; samples with AMH concentration < the LDV of the ultrasensitive assay (0.500 pmol/l) were re-measured using the picoAMH ELISA assay.